Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer
The treatment options for patients with head-and-neck squamous cell carcinoma (HNSCC) are limited when the disease progresses after taking platinum, a PD-1 inhibitor, and cetuximab. To develop new agents for managing such pretreated malignancies, therapies targeting carcinogenic pathways could be po...
| Published in: | Journal of Cancer Research and Practice |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-04-01
|
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00018 |